What it is
Mazdutide is a long-acting dual-agonist peptide that activates GLP-1 and glucagon receptors. By promoting satiety, curbing appetite, and helping regulate food intake, it supports a maintainable calorie deficit. Glucagon agonism may also raise energy expenditure and fat oxidation, encouraging steady fat reduction while preserving lean mass when paired with appropriate training and nutrition.
Mechanism of action
Engineered peptide activating both GLP-1 receptors (insulin secretion, gastric emptying delay, central appetite suppression) and glucagon receptors (hepatic glucose handling, lipolysis, increased energy expenditure).
Half-life: ~6 days โ supports once-weekly dosing.
Evidence summary
Phase 3 Chinese-population trial (NEJM 2025) established efficacy and safety for weight management. First-approval review (Drugs 2025) summarises pharmacology, regulatory pathway, and ongoing trial program.
Typical dosing protocols
- Initiate at 3 mg subcutaneous weekly; titrate every 4 weeks
- Maintenance: 6โ9 mg weekly
- Monitor for nausea / GI symptoms during titration
Side effects & safety
- GI: nausea, vomiting, diarrhea, especially during titration
- Possible elevations in heart rate
- Long-term safety data still accumulating
- โข Personal/family history of medullary thyroid carcinoma or MEN2
- โข Pregnancy
Cited studies
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.